Latest News
Yahoo! News Search Results for biotechAbbott to Buy Facet Biotech for 67% Premium (New York Times)
Abbott Laboratories announced late Tuesday that it had agreed to buy Facet Biotech for a net price of $450 million in cash, in a move aimed at expanding its drug pipeline, including for treatments for multiple sclerosis.
Abbott paying $450 million for Facet Biotech (AP via Yahoo! News)
Abbott Laboratories says it will buy Facet Biotech for about $450 million in cash, expanding the company's access to biotechnology drugs, including a potential treatment for multiple sclerosis.
Abbott to pay $450 million for Facet Biotech (AP via Yahoo! News)
Drug and medical products company Abbott Laboratories said Tuesday it will buy Facet Biotech Corp. for about $450 million in cash, expanding the company's access to biotechnology drugs, including a potential treatment for multiple sclerosis.
Facet Biotech Stock Soars on Abbott Bid (TheStreet.com)
Shares of drug maker Facet Biotech skyrocket after Abbott announced an acquisition bid valuing Facet at $27 a share.
Abbott Agrees to Buy Facet Biotech for $450 Million (Update1) (Bloomberg)
March 9 (Bloomberg) -- Abbott Laboratories , maker of the arthritis drug Humira, agreed to buy Facet Biotech Corp. for $27 a share, for a net $450 million, adding experimental medicines in cancer and immunology.
Abbott to Pay $450 Million for Facet Biotech (ABC News)
Abbott Labs to pay $450 million for Facet Biotech, expand access to biotechnology drugs Biotechnology - Biology - Business - Biotechnology and Pharmaceuticals - Directories
Abbott Agrees to Buy Facet Biotech for $450 Million (Update2) (BusinessWeek)
Abbott Laboratories, maker of the arthritis drug Humira, agreed to buy Facet Biotech Corp. for $27 a share in cash, for a net $450 million, adding experimental medicines in cancer and immunology.
Abbott Labs To Buy Facet Biotech For $722 Million (Fox News)
Abbott Labs To Buy Facet Biotech For $722 Million
Abbott paying $450 million for Facet Biotech (San Francisco Chronicle)
Abbott Laboratories says it will buy Facet Biotech for about $450 million in cash, expanding the company's access to biotechnology drugs, including a potential treatment for multiple sclerosis. Facet and its partner Biogen Idec plan to move the potential... Biogen Idec - Multiple sclerosis - Biotechnology - Health - Conditions and Diseases
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech (redOrbit)
ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.
|
|